Oral S-ketamine Study Reveals Bioavailability Challenges

Study Highlights Poor Bioavailability of Oral S-ketamine

A recent study published in OpenAlex has revealed that orally administered S-ketamine (S-KETPO) exhibits poor bioavailability compared to its intravenous counterpart (S-KETIV). Conducted as a randomized, double-blind, placebo-controlled, double-dummy, four-way crossover study, it involved 16 healthy participants receiving varying doses of S-KETPO and S-KETIV. The findings indicate that S-KETPO's bioavailability ranges between 9-12%, significantly lower than S-KETIV, raising concerns about its efficacy in treatment-resistant depression (TRD).

Mechanisms and Context of S-ketamine Administration

The study explored the pharmacokinetics and pharmacodynamics of S-KETPO, focusing on its systemic exposure and active metabolites. The first-pass effect significantly alters S-ketamine's bioavailability and the systemic exposure of its active metabolites, such as norketamine (S-NOR) and S-hydroxynorketamine (S-HNK). Peak plasma concentrations for S-KETPO were notably lower than those for S-KETIV, with S-KETPO 0.45 mg/kg showing inconsistent effects on vigilance and arousal.

Implications for Future Depression Treatments

These findings are crucial for dose selection in future TRD studies. The altered pharmacokinetic and pharmacodynamic profiles of oral S-ketamine suggest that current dosing strategies may need adjustment to ensure safety and therapeutic efficacy. Researchers and clinicians must consider these factors when designing and conducting future trials involving S-KETPO for depression treatment.

Risks and Unknowns in Oral S-ketamine Use

While safety was comparable across treatments, the limited central nervous system (CNS) effects and increased exposure to active metabolites raise concerns about the long-term safety and efficacy of oral S-ketamine. The study indicates that the oral route may not provide the same therapeutic benefits as intravenous administration, necessitating further research to optimize dosing and administration methods.

Looking Forward: The Future of S-ketamine Research

The study underscores the need for continued research into alternative administration routes for S-ketamine. Future studies should focus on optimizing oral formulations or exploring novel delivery methods to enhance bioavailability and therapeutic outcomes. As the field of psychedelic research evolves, understanding the intricacies of drug administration will be vital in developing effective treatments for TRD.